<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72512</article-id><article-id pub-id-type="doi">10.7554/eLife.72512</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in <italic>ESR1</italic> mutant breast cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-3584"><name><surname>Hosfield</surname><given-names>David J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250950"><name><surname>Weber</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250951"><name><surname>Li</surname><given-names>Nan-Sheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250952"><name><surname>Suavage</surname><given-names>Madline</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-276640"><name><surname>Joiner</surname><given-names>Carstyn F</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-276639"><name><surname>Hancock</surname><given-names>Govinda R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250953"><name><surname>Sullivan</surname><given-names>Emily A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250954"><name><surname>Ndukwe</surname><given-names>Estelle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250955"><name><surname>Han</surname><given-names>Ross</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250956"><name><surname>Cush</surname><given-names>Sydney</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126632"><name><surname>Lainé</surname><given-names>Muriel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250957"><name><surname>Mader</surname><given-names>Sylvie C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3588"><name><surname>Greene</surname><given-names>Geoffrey L</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6894-8728</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-45289"><name><surname>Fanning</surname><given-names>Sean W</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9428-0060</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Ben May Department for Cancer Research</institution>, <institution>University of Chicago</institution>, <addr-line><named-content content-type="city">Chicago</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Institute for Research in Immunology and Cancer</institution>, <institution>Université de Montréal</institution>, <addr-line><named-content content-type="city">Montréal</named-content></addr-line>, <country>Canada</country></aff><aff id="aff3"><institution content-type="dept">Department of Cancer Biology</institution>, <institution>Loyola University Chicago</institution>, <addr-line><named-content content-type="city">Maywood</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-31092"><name><surname>Zwart</surname><given-names>Wilbert</given-names></name><role>Reviewing editor</role><aff><institution>Netherlands Cancer Institute</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>sfanning@luc.edu</email> (SF);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>05</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e72512</elocation-id><history><date date-type="received"><day>27</day><month>07</month><year>2021</year></date><date date-type="accepted"><day>13</day><month>05</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Hosfield et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Hosfield et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72512-v2.pdf"/><abstract><p>Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend ERα cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ERα cellular lifetime/accumulation and are pure antagonists. Activating somatic <italic>ESR1</italic> mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in <italic>ESR1</italic> mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ERα cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene derivatives that maintained the drug's antagonistic activities while uniquely tuning ERα cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ERα cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ERα ligand binding domain in complex with the methylated lasofoxifene derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S <italic>ESR1</italic>. Together these results show that chemical reduction of ERα cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in <italic>ESR1</italic> mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ERα, which is crucial for achieving desired SERM or SERD profiles.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009634</institution-id><institution>Susan G. Komen</institution></institution-wrap></funding-source><award-id>CCR19608597</award-id><principal-award-recipient><name><surname>Fanning</surname><given-names>Sean W</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Ludwig Fund for Metastasis Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Greene</surname><given-names>Geoffrey L</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mader</surname><given-names>Sylvie C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in the execution of this study.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Sean W Fanning, In the interest of transparency, Dr. Fanning's laboratory receives sponsored research funds from Olema Oncology Inc. Olema was not involved in this study. This work has no impact on the company..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All protein crystal structures have been deposited in the PDB under accession codes: 6PSJ, 7KBS, 7UJC, 7UJ8, 7UJM, 7UJY, 7UJF, 7UJW, 7UJO, 7UJ7, 6V8T, and 6VPF.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2020">2020</year><source>Bazedoxifene in Complex with Y537S Estrogen Receptor Alpha Ligand Binding Domain</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6PSJ">https://www.rcsb.org/structure/6PSJ</ext-link><comment>PDB, 6PSJ</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab></person-group><year iso-8601-date="2020">2020</year><source>Estrogen Receptor Alpha Ligand Binding Domain in Complex with Raloxifene</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/7KBS">https://www.rcsb.org/structure/7KBS</ext-link><comment>PDB, 7KBS</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Raloxifene</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/7KCA">https://www.rcsb.org/structure/7KCA</ext-link><comment>PDB, 7UJC</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with 4-Hydroxytamoxifen</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6V87">https://www.rcsb.org/structure/6V87</ext-link><comment>PDB, 7UJ8</comment></element-citation><element-citation id="dataset5" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain in Complex with a Methylated Lasofoxifene Derivative That Increases Receptor Resonance Time in the Nucleus of Breast Cancer Cells</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/7KCD">https://www.rcsb.org/structure/7KCD</ext-link><comment>PDB, 7UJM</comment></element-citation><element-citation id="dataset6" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with a Methylated Lasofoxifene Derivative that Enhances Estrogen Receptor Alpha Nuclear Resonance Time</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6VPK">https://www.rcsb.org/structure/6VPK</ext-link><comment>PDB, 7UJY</comment></element-citation><element-citation id="dataset7" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain in Complex with a Methylated Lasofoxifene Derivative with Selective Estrogen Receptor Degrader Properties</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6VMU">https://www.rcsb.org/structure/6VMU</ext-link><comment>PDB, 7UJF</comment></element-citation><element-citation id="dataset8" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with a Methylated Lasofoxifene Derivative that Possesses Selective Estrogen Receptor Degrader Activities</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6VVP">https://www.rcsb.org/structure/6VVP</ext-link><comment>PDB, 7UJW</comment></element-citation><element-citation id="dataset9" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain in Complex with RU39411</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6VIG">https://www.rcsb.org/structure/6VIG</ext-link><comment>PDB, 7UJO</comment></element-citation><element-citation id="dataset10" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2022">2022</year><source>Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with RU39411</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6VJ1">https://www.rcsb.org/structure/6VJ1</ext-link><comment>PDB, 7UJ7</comment></element-citation><element-citation id="dataset11" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2019">2019</year><source>Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with LSZ102</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6V8T">https://www.rcsb.org/structure/6V8T</ext-link><comment>PDB, 6V8T</comment></element-citation><element-citation id="dataset12" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fanning SW</collab><collab>Greene GL</collab></person-group><year iso-8601-date="2020">2020</year><source>Estrogen Receptor Alpha Ligand Binding Domain in Complex with the Selective Estrogen Receptor Modulator Clomiphene</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6VPF">https://www.rcsb.org/structure/6VPF</ext-link><comment>PDB, 6VPF</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-72512-supp-v2.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>